Home/ Stocks/ ALLO

Allogene Therapeutics, Inc. Common Stock

ALLO XNAS

$2.01 +0.02 (+1.17%) ▲ 15-min delayed

Open

$1.98

High

$2.02

Low

$1.96

Volume

3.70M

Market Cap

$679.95M

About Allogene Therapeutics, Inc. Common Stock

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 152 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-42,607,000	$-0.18
FY 2025	$0	$-190,886,000	$-0.87
Q3 2025	$0	$-41,400,000	$-0.19
Q1 2025	$0	$-59,733,000	$-0.28

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for ALLO yet. Check out our latest market news or earnings calendar.

Get ALLO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Allogene Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.